Literature DB >> 1096982

Ataxia-telangiectasia: some historic, clinical and pathologic observations.

E Boder.   

Abstract

Although an isolated clinical case report was published in 1926 and another in 1941, ataxia-telangiectasia (A-T) was not established as a distinct entity until 1957, when it was first delineated clinicopathologically. Susceptibility to sinopulmonary infection was identified as the main cause of death and as the third major component of the syndrome; its heredofamilial nature was documented, and it was designated "ataxia-telangiectasia." In a later review of 101 published cases, lymphoreticular malignancy emerged as the second most frequent cause of death. Although the thymus was found to be absent in the first reported autopsy in 1957 and the serum IgA deficiency was first recorded in 1961, A-T was not established as an immunodeficiency disease until 1963. Thymic abnormality and dysgammaglobulinemia explain the 2 main causes of death, sinopulmonary and neoplastic, but the immunodeficiency is probably not the central defect. It does not appear to explain either of the 2 main clinical diagnostic keys, the ataxia and the telangiectasia, or any of the other seemingly unrealted multisystemic facets of this complex disorder. Some of our most provocative long-term clinical observations and recent pathologic findings in our series of 9 autopsies are discussed.

Entities:  

Mesh:

Year:  1975        PMID: 1096982

Source DB:  PubMed          Journal:  Birth Defects Orig Artic Ser        ISSN: 0547-6844


  23 in total

1.  Progressive vitiligo, mental retardation, facial dysmorphism, and urethral duplication without chromosomal breakage or immunodeficiency.

Authors:  P Labrune; R Assathiany; D Penso; M Odièvre
Journal:  J Med Genet       Date:  1992-08       Impact factor: 6.318

2.  Evaluation and management of pulmonary disease in ataxia-telangiectasia.

Authors:  Sharon A McGrath-Morrow; W Adam Gower; Cynthia Rothblum-Oviatt; Alan S Brody; Claire Langston; Leland L Fan; Maureen A Lefton-Greif; Thomas O Crawford; Michelle Troche; John T Sandlund; Paul G Auwaerter; Blaine Easley; Gerald M Loughlin; John L Carroll; Howard M Lederman
Journal:  Pediatr Pulmonol       Date:  2010-09

3.  Transfer factor therapy in ataxia--telangiectasia.

Authors:  A I Berkel; F Ersoy; L B Epstein; L E Spitler
Journal:  Clin Exp Immunol       Date:  1977-09       Impact factor: 4.330

Review 4.  DNA repair disorders.

Authors:  C G Woods
Journal:  Arch Dis Child       Date:  1998-02       Impact factor: 3.791

5.  Epstein-Barr virus-related antibody patterns in ataxia-telangiectasia.

Authors:  A I Berkel; W Henle; G Henle; G Klein; F Ersoy; O Sanal
Journal:  Clin Exp Immunol       Date:  1979-02       Impact factor: 4.330

6.  Low-dose irradiation prior to bone marrow transplantation results in ATM activation and increased lethality in Atm-deficient mice.

Authors:  J Pietzner; B M Merscher; P C Baer; R P Duecker; O Eickmeier; D Fußbroich; P Bader; D Del Turco; R Henschler; S Zielen; R Schubert
Journal:  Bone Marrow Transplant       Date:  2016-01-11       Impact factor: 5.483

7.  Spontaneous and induced chromosome breakage in chorionic villus samples: a cytogenetic approach to first trimester prenatal diagnosis of ataxia telangiectasia syndrome.

Authors:  J Llerena; M Murer-Orlando; M McGuire; L Zahed; R J Sheridan; A C Berry; M Bobrow
Journal:  J Med Genet       Date:  1989-03       Impact factor: 6.318

8.  Presumed ataxia-telangiectasia in a man.

Authors:  T R Terenty; P Robson; J N Walton
Journal:  Br Med J       Date:  1978-09-16

9.  Effects of antioxidants on cancer prevention and neuromotor performance in Atm deficient mice.

Authors:  Ramune Reliene; Sheila M Fleming; Marie-Françoise Chesselet; Robert H Schiestl
Journal:  Food Chem Toxicol       Date:  2007-08-29       Impact factor: 6.023

10.  Ataxia telangiectasia. Evaluation of radiosensitivity in cultured skin fibroblasts as a diagnostic test.

Authors:  R Cox; G P Hosking; J Wilson
Journal:  Arch Dis Child       Date:  1978-05       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.